HAWTHORNE, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced Anthony Caggiano, M.D., PhD., has been promoted to Vice President, Preclinical Development and joined the Company’s management team. Dr. Caggiano will continue to manage the Preclinical and Research & Development departments, as well as oversee Acorda’s preclinical programs that aim to develop novel approaches to the treatment of multiple sclerosis (MS), spinal cord injury (SCI) and related neurological disorders.
